Remove Ethics Remove Finance Remove Pharmaceuticals Remove Process
article thumbnail

How Merck Is Trying to Keep Disrupters at Bay

Harvard Business Review

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. The translation involves people and processes.

article thumbnail

Why Are Some Sectors (Ahem, Finance) So Scandal-Plagued?

Harvard Business Review

billion due to derelict mortgage and foreclosure processes. initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement.